A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Trial Identifier:	D822FC00008
Sponsor:	AstraZeneca
Collaborator:	Acerta Pharma B.V
NCTID::	NCT04489797
Start Date:	July 2020
Primary Completion Date:	August 2020
Study Completion Date:	August 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English version

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States of America, CA	Anaheim, CA, United States of America, 92801

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.